Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis

Kathleen W. Zhang, Keith E. Stockerl-Goldstein, Daniel J. Lenihan

Research output: Contribution to journalReview articlepeer-review

48 Scopus citations


Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue. Traditionally, treatment options for light chain (AL) and transthyretin (ATTR) amyloidosis have been limited. However, there are now multiple novel therapeutics in development and several therapeutics recently approved that promise to revolutionize clinical management of AL and ATTR. Most of these agents disrupt specific stages of amyloidogenesis such as light chain or transthyretin protein production, formation of amyloidogenic intermediates, or amyloid fibril aggregation. Others aim to remove existing amyloid tissue deposits using monoclonal antibody technology. Although these advances represent an important step forward in the care of cardiac amyloidosis patients, additional studies are needed to define the optimal treatment paradigms for AL and ATTR and to validate clinical, imaging, or serum biomarker strategies that may confirm a cardiac response to therapy.

Original languageEnglish
Pages (from-to)438-448
Number of pages11
JournalJACC: Basic to Translational Science
Issue number3
StatePublished - Jun 2019


  • cardiac amyloidosis
  • clinical trials
  • therapeutics


Dive into the research topics of 'Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis'. Together they form a unique fingerprint.

Cite this